triheptanoin as a novel therapy for metabolic myopathies ... · triheptanoin as a novel therapy for...

24
L. Borgia L. Borgia 1 1 , S.J. Valberg, M.E. McCue, J. , S.J. Valberg, M.E. McCue, J. Pagan, and C. Roe Pagan, and C. Roe 1 1 University of Minnesota College of Veterinary Medicine St Paul M University of Minnesota College of Veterinary Medicine St Paul M N N Triheptanoin as a novel therapy for Triheptanoin as a novel therapy for metabolic metabolic myopathies myopathies and muscular and muscular dystrophies dystrophies

Upload: phungnguyet

Post on 21-Apr-2018

219 views

Category:

Documents


5 download

TRANSCRIPT

Page 1: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

L. BorgiaL. Borgia11, S.J. Valberg, M.E. McCue, J. , S.J. Valberg, M.E. McCue, J. Pagan, and C. Roe Pagan, and C. Roe

1 1 University of Minnesota College of Veterinary Medicine St Paul MUniversity of Minnesota College of Veterinary Medicine St Paul MNN

Triheptanoin as a novel therapy for Triheptanoin as a novel therapy for metabolic metabolic myopathiesmyopathies and muscular and muscular

dystrophiesdystrophies

Page 2: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

IntroductionIntroduction

Amylase-resistant abnormal polysaccharide in cells

Polysaccharide Storage Myopathy (PSSM), a genetic neuromuscular disease found in horses

Increased synthesis of glycogen and accumulation of abnormal polysaccharide in muscleIncreased synthesis of glycogen (GYS1).

Page 3: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Cell damage and impaired Cell damage and impaired energy metabolism may deplete energy metabolism may deplete CAC intermediatesCAC intermediatesTriheptanoin (C7) shown to Triheptanoin (C7) shown to provide C3 to replenish depleted provide C3 to replenish depleted CAC intermediatesCAC intermediatesAbsorption of C7 occurs in PSSM Absorption of C7 occurs in PSSM horseshorses

C7 C5 propionyl CoA m-malonyl CoA+ acetyl CoA

beta oxidation of C18

Horses consuming TH or CO

TH CO 0.00

0.01

0.02

0.03

C7μ

M

malate

succinatesuccinyl-CoA

α-ketoglutarate

isocitrate

oxaloacetate

fumarate

citrate

acetyl-CoA

Page 4: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Triheptanoin (TH) used to treat MCAD deficiency in humansWider use suggested for similar metabolic myopathies in humans

Animal Model: PSSMAnimal Model: PSSM

Page 5: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Current PSSM TreatmentCurrent PSSM Treatment

Post exercise serum creatine kinase activity (CK) affected by diet:Therapeutic diet– Low starch– High long chain fat corn oil (CO)

linoleic (C18:2) and oleic acid (C18:1)

Page 6: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Hypothesis/ObjectivesHypothesis/ObjectivesHypothesis: Provision of triheptanoin (C7), which may replete CAC intermediates, will be more effective than C18 in ameliorating signs of rhabdomyolysis and reducing serum CK activity.rhabdomyolysis and reducing serum CK activity.

Rationale: rhabdomyolysis in may result in loss of CAC intermediates impairing cellular energy metabolism

Objectives: 1. Objectives: 1. To determine if serum CK activity following submaximal To determine if serum CK activity following submaximal exercise is lower on triheptanoin vs. corn oil. exercise is lower on triheptanoin vs. corn oil.

2.2. To determine if substrate availability during submaximal exerciTo determine if substrate availability during submaximal exercise is se is impacted by provision of triheptanoin or corn oil.impacted by provision of triheptanoin or corn oil.

Page 7: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

DesignDesign

Forage base:Forage base:–– 1.5% of 1.5% of bwbw in grass hayin grass hay–– 0.5 kg ration balancer0.5 kg ration balancer

Oil diets:Oil diets:–– 1.5 kg hay cubes 1.5 kg hay cubes –– 1.5 ml/kg/day TH or CO1.5 ml/kg/day TH or CO–– Divided 3 feeding/dayDivided 3 feeding/day

IsocaloricIsocaloric diets providing 25 diets providing 25 MCalMCal/day /day corn oil or triheptanoincorn oil or triheptanoin

Randomized crossRandomized cross--over over design with 2 blocks design with 2 blocks Each block lasted 3 wksEach block lasted 3 wks1 wk washout between 1 wk washout between blocksblocksHorses exercised 5 Horses exercised 5 days/wk on each blockdays/wk on each blockDaily blood samples 4 hr Daily blood samples 4 hr after exercise for serum after exercise for serum CK activityCK activity

Page 8: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Materials and Methods Materials and Methods -- HorsesHorses

8 horses previously 8 horses previously diagnosed with PSSM diagnosed with PSSM based on amylase based on amylase resistant polysaccharideresistant polysaccharide6 mares, 1 gelding , 1 colt6 mares, 1 gelding , 1 colt2 2 –– 14 yrs of age (6.25 14 yrs of age (6.25 ±±3.9 yrs3.9 yrs))Stall rested for a minimum Stall rested for a minimum of 3 wks prior to start of of 3 wks prior to start of treadmill exercisetreadmill exercise

Page 9: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Materials and MethodsMaterials and Methods--Starch dietStarch dietIndividual treadmill exercise protocol established Individual treadmill exercise protocol established

25 25 MCalMCal/day /day –– Forage Base Forage Base

1.5% 1.5% bwbw grass haygrass hay0.5 kg ration 0.5 kg ration balancerbalancer

–– Concentrate per Concentrate per 500kg500kg

1.7 kg sweet feed1.7 kg sweet feed1 kg rice bran1 kg rice bran

Exercise toleranceExercise tolerance–– Week 1: Week 1:

intervals walk and intervals walk and trot (2 min) trot (2 min)

–– Week 2 & 3:Week 2 & 3:Establish individual Establish individual exercise protocol exercise protocol (daily treadmill (daily treadmill exercise target)exercise target)

Page 10: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Materials and Methods Materials and Methods -- TreadmillTreadmill

Same individual exercise protocol Same individual exercise protocol across blocksacross blocksSame handler for each horseSame handler for each horseHandlers blinded to dietHandlers blinded to dietExercise terminated prematurely Exercise terminated prematurely if horse became stiff, excessive if horse became stiff, excessive sweating or unable to keep pace sweating or unable to keep pace Subsequent exercise session was Subsequent exercise session was reduced to 2 min if overt signs of reduced to 2 min if overt signs of ER or CK> 50,000 U/L ER or CK> 50,000 U/L Exercise duration gradually Exercise duration gradually increased increased

Page 11: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Materials and Methods Materials and Methods -- Exercise testExercise test

Exercise testExercise testLast day of each Last day of each block. 2 min block. 2 min intervals walk intervals walk (1.9 (1.9 m/sm/s) trot ) trot (3(3--4.7 4.7 m/sm/s) for ) for 15 min15 minBlood collected Blood collected pre/post pre/post exercise via exercise via jugular catheter jugular catheter

Page 12: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Muscle needle Muscle needle biopsies biopsies obtained obtained pre/immediately pre/immediately post exercise post exercise through same through same incision, snap incision, snap frozen in liquid Nfrozen in liquid NSerum CK Serum CK measured 4 hr measured 4 hr post exercisepost exercise

Materials and Methods Materials and Methods -- Exercise testExercise test

Page 13: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Statistical AnalysisStatistical AnalysisCK CK –– repeated measures ANOVA log repeated measures ANOVA log

CKCK–– Not all horses achieved daily Not all horses achieved daily

exercise target. exercise target. ANCoVAANCoVA log CK log CK using % daily exercise achieved using % daily exercise achieved as covariant.as covariant.

Pre and post exercise blood Pre and post exercise blood samplessamples–– Glucose, insulin, NEFA, Glucose, insulin, NEFA,

acylcarnitines acylcarnitines –– 2 way ANOVA2 way ANOVA

Pre exercise glycogen Pre exercise glycogen (muscle)(muscle)–– t testt test

Reported as mean Reported as mean ±± standard standard deviationdeviation

Page 14: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Results: CKResults: CKMean CK activityMean CK activityTH > grainTH > grainTH > COTH > COCO < grainCO < grain

Exercise ToleranceExercise Tolerance–– THTH

37 days horses < target 37 days horses < target (84% achieved)(84% achieved)

–– COCO5 days horses < target 5 days horses < target (99% achieved)(99% achieved)

Mean CK values

Grain Triheptanoin Corn oil0

1000

2000

3000

4000

5000

6000

CK

(U/L

)

a

b

c

Mean daily CK values

0 4 8 12 16100

1000

10000

graintriheptanoin

corn oil

Day

CK

(U/L

)

Page 15: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Results: SubstratesResults: Substrates

Glycogen

TH CO0

100200300400500600700800

Diet

mm

ol/k

g

GlycogenGlycogen–– Diet effectDiet effect

No difference No difference between blocksbetween blocks

Page 16: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Results: Plasma Results: Plasma CarnitinesCarnitines

C18:2 acylcarnitineC18:2 acylcarnitine–– Diet effectDiet effect

TH<COTH<CO

–– Exercise Effect Exercise Effect Pre < PostPre < Post

C3 acylcarnitineC3 acylcarnitine–– Diet effectDiet effect

TH>COTH>CO

–– Exercise Effect Exercise Effect NoneNone

C18:2 acylcarnitine

TH pre TH Post CO Pre CO Post0.000

0.005

0.010

0.015

0.020

0.025

0.030

0.035

C3 acylcarnitine

TH CO0

1

2

Diet

μM

pre

prepost

post

Page 17: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Results: SubstratesResults: Substrates

Diet EffectDiet Effect–– Insulin Insulin

TH > CO TH > CO CO < grainCO < grain

–– GlucoseGlucoseNo difference No difference

Exercise Effect Exercise Effect –– Glucose and InsulinGlucose and Insulin

Pre > Post exercisePre > Post exercise

Insulin pre and post exercise

Grain TH CO0

5

10

15

20

25

30

35

prepre

prepost post post

Diet

μm

ol/m

l

Page 18: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Results: SubstratesResults: Substrates

NEFANEFA–– Diet effectDiet effect

TH<COTH<COGrain<C0Grain<C0

–– Exercise Effect Exercise Effect No differenceNo difference

NEFA Pre/Post Exercise

Grain TH CO0.00

0.05

0.10

0.15

postpost

post

pre pre

pre

Dietm

mol

/l

Page 19: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

DiscussionDiscussion

Plasma acylcarnitine concentrations suggested Plasma acylcarnitine concentrations suggested that TH was absorbed and metabolized to C3, C5 that TH was absorbed and metabolized to C3, C5 potentially providing CAC intermediates.potentially providing CAC intermediates.Rather than a beneficial effect, TH exacerbated Rather than a beneficial effect, TH exacerbated muscle damage during exercise as indicated by muscle damage during exercise as indicated by serum CK activity.serum CK activity.Further, TH caused exercise intolerance as Further, TH caused exercise intolerance as indicated by inability to achieve daily exercise indicated by inability to achieve daily exercise target. target. Detrimental effect of TH was not related to higher Detrimental effect of TH was not related to higher muscle glycogen concentrationsmuscle glycogen concentrations

Page 20: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

DiscussionDiscussionTH produced plasma insulin TH produced plasma insulin concconcsimilar to grain (> CO). similar to grain (> CO). –– Increased CAC intermediates Increased CAC intermediates

““secretagoguessecretagogues”” may induce insulin may induce insulin secretion by pancreassecretion by pancreas

Activation of lipoprotein lipase by Activation of lipoprotein lipase by insulin may explain low NEFA insulin may explain low NEFA concentrations on grain and TH.concentrations on grain and TH.Lack of beneficial effect of TH Lack of beneficial effect of TH may be related to low NEFA and may be related to low NEFA and inadequate long chain fats inadequate long chain fats available for metabolism.available for metabolism.

Page 21: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

DiscussionDiscussionCorn oil had a beneficial effect Corn oil had a beneficial effect and lowered serum CK activity.and lowered serum CK activity.Lower plasma insulin on CO Lower plasma insulin on CO diet resulted in higher diet resulted in higher concentrations of plasma concentrations of plasma NEFAsNEFAs available for available for ββ--oxidation oxidation during exercise.during exercise.Plasma C18:2 and C18:1 Plasma C18:2 and C18:1 acylcarnitine increased with acylcarnitine increased with exercise, suggesting dietary exercise, suggesting dietary long chain fats were long chain fats were metabolized by PSSM horses.metabolized by PSSM horses.

Page 22: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

ConclusionConclusion

TH may be of benefit as a therapeutic diet TH may be of benefit as a therapeutic diet for carefully selected metabolic for carefully selected metabolic myopathiesmyopathies–– MCADsMCADs–– PompePompe diseasedisease–– PatientPatient’’s endocrine status should be evaluateds endocrine status should be evaluated

TH may not be of benefit to those with TH may not be of benefit to those with diabetes or those needing LC fats for diabetes or those needing LC fats for energy metabolismenergy metabolism

Page 23: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

Next StepsNext Steps

Analysis of the effect of starch, sugar, and Analysis of the effect of starch, sugar, and fructanfructan concentrations in forages (hay) on concentrations in forages (hay) on horses with PSSMhorses with PSSMContinue to explore mechanisms of this Continue to explore mechanisms of this disorderdisorder

Page 24: Triheptanoin as a novel therapy for metabolic myopathies ... · Triheptanoin as a novel therapy for ... Hypothesis/Objectives Hypothesis: ... Materials and Methods-Starch diet

AcknowledgementsAcknowledgements

Michelle Michelle LucioLucio, April Holden, Krista Steffenhagen, April Holden, Krista SteffenhagenSupported by Office of Clinical and Translational Supported by Office of Clinical and Translational Research, Morris Animal Foundation, Eric Research, Morris Animal Foundation, Eric MarzolfMarzolfMuscular Dystrophy grant, and University of Muscular Dystrophy grant, and University of Minnesota Equine Center. Grand opening October Minnesota Equine Center. Grand opening October 15 at 2pm!15 at 2pm!